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Case Report

A Case of Parkinson’s Disease Symptom Reduction with Intravenous
NAD+
Erin Gadol1*, Richard F. Mestayer1,2, Ross Grant3,4, Yevgeniy Grigoryev5, Susan B.
Gibson6, and Michael Happel7
1NAD

Research, Incorporated, USA

2Springfield

Wellness Center, USA

3Australasian

Research Institute, Australia

4Department

of Pharmacology, School of Medical Sciences, University of New South Wales, Australia

5Department

of Biology, City College of New York, USA

6School

of Natural and Behavioral Sciences, William Carey University, USA

7Northlake

Neurological Institute, USA

*Corresponding authors: Erin Gadol, NAD Research, Incorporated, 32900 Pitcher Road, Springfield, LA 70462 USA,
Tel: +1 225-414-0602; Fax: +1 225-294-5944; E-mail: egadol000@citymail.cuny.edu
Received: March 02, 2019; Accepted: March 28, 2019; Published: April 05, 2019
Copyright: ©2019 Gadol E, et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Citation: Gadol E, Mestayer RF, Grant R, Grigoryev Y, Gibson SB, et al. (2019) A Case of Parkinson’s Disease Symptom
Reduction with Intravenous NAD+. Case Rep Lit Rev 3(1): 100021.

Abstract
Neurological deterioration in Parkinson’s disease (PD) and resulting motor dysfunction arises from Lewy body
formation and dopaminergic neuronal death in the substantia nigra. Two factors contributing to PD-related apoptosis
and subsequent motor dysfunction involve improper cellular metabolism of reactive oxygen species (ROS) and
impaired mitochondrial functionality. The co-factor Nicotinamide Adenine Dinucleotide (NAD+), reduction of which
has been implicated in the development of neurodegenerative disease, is a critical player in maintaining cellular redox
metabolism and mitochondrial function. We present a case study of a PD patient who has become near asymptomatic
through the use of intravenous (I.V.) NAD+. This report documents the patient’s initial symptom changes while
receiving I.V. NAD+ over the course of eight treatment days, with two non-treatment days in between. The treatment
entailed 1500 mg. I.V. NAD+ on day one, 1000 mg. I.V. NAD+ on day two, and 750 mg. I.V. NAD+ on day three.
Symptoms were documented by medical staff for the next two days of non-treatment. Following this, 750 mg. I.V. NAD+
was administered on treatment days four and five, 500 mg. I.V. NAD+ on treatment days six and seven, and 750 mg.
I.V. NAD+ on treatment day eight. Over the course of treatment, the patient’s hand tremors decreased to a mild level,
permitting coordinated use of a pen and utensils. Hand tremors were absent on days one and six. Visual hallucinations
were absent on days two through seven. To maintain tremors at a tolerable level, aftercare involved I.V. NAD+ every
four to six weeks, with a daily regimen of 300 mg/ml NAD+ nasal spray. Moreover, the patient discontinued PD-related
medication, thereby preventing visual hallucination side effects. Although more research on NAD+ in clinical use is
needed, the evidence obtained from these symptom improvements indicates NAD+ as having the potential for clinical
use in at least a subset of PD sufferers.
Keywords: Parkinson's disease, neurodegeneration, NAD+
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Introduction
Recognized as the world’s second most common adult-onset neurodegenerative disease, Parkinson’s disease
(PD) is a progressively debilitating disorder characterized by disturbances in motor functionality, including resting
tremors, bradykinesia and muscular rigidity [1]. Side effects of commonly prescribed anti-PD treatment may also result
in medication-induced visual hallucinations and paranoid delusions [2].
It is understood that neurological deterioration in PD results from the formation of Lewy bodies and the
selective death of dopaminergic neurons within the substantia nigra. Increasing evidence asserts the interplay of
improper cellular metabolism of reactive oxygen species (ROS), coincided with impaired mitochondrial function, as
two interwoven factors contributing to PD-related apoptosis and subsequent motor dysfunction [3,4]. The co-factor
nicotinamide adenine dinucleotide (NAD+) is a critical player in healthy cellular redox metabolism and mitochondrial energy
production [5,6]. In fact, a decrease in available NAD+ has been implicated in the development of neurodegenerative disease
[7]. Thus, it may be worth considering the potential effects flowing from a dysregulation of this central molecule in

understanding the metabolic dysfunctions driving the development of PD and subsequent treatment.

Case Report
We report a case of a patient diagnosed with PD and documents his symptom changes over eight days of
intravenously administered supplemental NAD+ therapy. An 80-year-old man with a fourteen-year history of PD, with
no other documented health or psychiatric illnesses, sought treatment at an outpatient clinic specializing in intravenous
NAD+ therapy. He was observed over a period of eight treatment days, with a break of two non-treatment days in
between to accommodate a prior engagement.
Before his arrival, his symptoms included severe bilateral hand tremors, inability to hold utensils or sign his
name, peripheral hallucinations, decreased social interaction, and overall compromised quality of life. The patient
utilized 1.5 mg per day of Mirapex to treat his symptoms at the time of intake. The following observations were
documented by medical staff as well as by the patient himself.
Prior to infusion on day one, the patient reported experiencing severe bilateral hand tremors and visual
hallucinations. Approximately two hours into his first NAD+ infusion, his tremors became unnoticeable, remaining so
throughout the rest of that day’s treatment, and only returning mildly in the evening. Additionally, the patient was
finally able to hold utensils comfortably. On treatment day two, some hand tremors were present throughout the day,
yet were significantly improved compared to time of arrival. There was a newly marked absence of visual hallucinations.
On treatment day three, he experienced minor hand tremors throughout the day.
The following two days were days of non-treatment. On the first day of non-treatment, the patient reported a
mild shaking of his right thumb upon waking, and slight tremors in both hands as the day progressed. By the next day
of non-treatment, the patient reported that his hand tremors increased somewhat with movement, yet not while at rest,
as the day progressed.
Commencing day four of treatment, the patient reported slight tremors upon waking which remained mild
throughout the day. On treatment day five, while he still experienced mild bilateral tremors throughout the day, it was
observed that he could write legibly. On treatment day six, he reported slight shaking in both thumbs only upon waking,
which later disappeared throughout treatment. On treatment day seven, he reported no feeling of shakiness in either hand
upon waking, although shakiness returned slightly as the day progressed. Upon waking the next morning prior to the eighth
day of infusion, the patient only reported some peripheral hallucinations. His hallucinations disappeared over the course

of this final, eighth NAD+ infusion. He was observed to have slight hand tremors, which remained throughout this
treatment day. By the end of his treatment program, he had received a total of 6500 mg of I.V. NAD+ (Table 1).
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Table 1: Summary of Treatment Days and Corresponding PD Symptoms
Amount of NAD+
Delivered (mg)

Day

Baseline

0

PD Symptoms and Symptom Changes
•
•
•
•
•

Severe bilateral hand tremors
Inability to hold utensils
Inability to sign name and write legibly
Visual hallucinations
Decreased social interactions

•
•

Hand tremors absent, returning slightly into
evening
Ability to hold utensils*

Day 1
Treatment Day 1

1,500

Day 2
Treatment Day 2

1,000

•
•

Mild hand tremors present
Visual hallucinations disappear

Day 3
Treatment Day 3

750

•

Mild hand tremors present

Day 4
Non-treatment

0

•

Mild hand tremors present

Day 5
Non-treatment

0

•

Mild hand tremors present

Day 6
Treatment Day 4

750

•

Mild hand tremors present

Day 7
Treatment Day 5

750

•
•

Mild hand tremors present
Ability to write legibly*

Day 8
Treatment Day 6

500

•

Hand tremors absent

Day 9
Treatment Day 7

500

•

Mild Hand tremors present

Day 10
Treatment Day 8

750

•

Peripheral hallucinations present in morning, but
later disappear
Hand tremors present with movement only

*This

•

symptom change began on this day and follows into the patient’s current state.

For follow-up PD maintenance, the patient regularly receives 1,000 mg of intravenous NAD+ boosters,
approximately every 4-6 weeks. He also maintains his symptoms with a 300 mg/ml NAD + nasal spray (0.1 ml per spray),
twice in each nostril daily. This regimen continues to maintain his tremors at a tolerable, mild rate, allowing him significantly
greater participation in daily activities (e.g. he has begun riding a bike again). In addition, as the patient’s neurological
symptoms have been significantly improved, he has been able to discontinue his PD-related medication. Using NAD+

therapy alone has also enabled him to live without visual hallucinations. In all, he reports his quality of life as far more
manageable and enjoyable, allowing him the ability to participate in many activities previously rendered impossible.
The reduction in PD symptoms this patient experienced during initial treatment, including the eventual
discontinuation of anti-PD medication, lends significant anecdotal support for the use of NAD+ as a potentially useful
treatment for at least a subset of Parkinson’s disease patients. Although the biochemical processes involved in PD
pathogenesis are complex and varying between cases, the association between increased oxidative damage and reduced
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NAD+ availability in the pathobiochemistry of neurodegenerative disease provide at least some rationale for the marked
symptom reduction in this case [7,8]. Additionally, as prior research suggests, increasing the availability of NAD+ to
dopaminergic neurons in the nigrostriatal tracts may have the potential to promote healthy mitochondrial function and
DNA repair. Moreover, in a murine model, NAD+ supplementation has demonstrated neuronal restoration following
the induction of neurodegeneration [9,10]. Furthermore, one recent study has directly linked NAD+ precursor
administration to preventing dopaminergic neuronal loss in PD patient derived induced pluripotent stem cells [11].
Overall, our current study supports the notion that NAD+ supplementation may be increasing cellular resilience to
ongoing dopaminergic neuronal loss in this particular PD sufferer.
Although the evidence obtained from observations reported for this single individual does not claim that NAD +
targets disease pathogenesis, the significant clinical improvements indicate that NAD+ therapy can alleviate symptoms
in at least a subset of PD sufferers. These extraordinary observations warrant further clinical investigation of NAD+ and
its potential to modulate key cellular processes impaired in neurodegenerative diseases such as PD.
While further research will be needed, these observations implicate that NAD+ supplementation can have
therapeutic value for at least symptomatic treatment in this neurodegenerative disease.
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